secwatch.observer — SEC 8-K summary
======================================

Issuer:     GENELUX Corp (GNLX)
CIK:        0001231457
Form:       8-K
Filed at:   2026-01-05T23:59:59+00:00
Accession:  0001493152-26-000270
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 7.01, 9.01, 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Genelux reports 33% ORR in SCLC and 60% DCR in NSCLC with systemic Olvi-Vec
---------------------------------------------------------------------------

- SCLC Phase 1b/2: 33% ORR (3/9 PRs), 67% DCR; highest dose cohort 67% ORR (2/3) with tumor shrinkage ~55% and ~85%.
- NSCLC Phase 2 VIRO-25: 60% DCR (3/5 patients); tumor size changes -18.9% and -22.7% in two of three DCR patients.
- Durability signals: two SCLC PR patients had PFS of 12.1 mo (1 prior line) and 7.7 mo (4 prior lines).
- Topline Phase 3 ovarian cancer data expected H2 2026; additional lung cancer interim readouts throughout 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1231457/000149315226000270/0001493152-26-000270-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1231457/000149315226000270/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-000270

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer